X4 Pharmaceuticals (XFOR) Cash from Operations (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Cash from Operations for 10 consecutive years, with -$20.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations rose 30.44% year-over-year to -$20.8 million; the trailing twelve-month figure through Jun 2026 stood at -$83.7 million (up 23.37% YoY), and the FY2025 full-year result was -$85.6 million, up 34.59% from the prior year.
• Cash from Operations declined to -$20.8 million in Q2 2026 per XFOR's latest filing, from -$19.6 million in the prior quarter.
• Across five years, Cash from Operations topped out at -$12.4 million in Q1 2025 and bottomed at -$68.8 million in Q3 2023.
• Historically, Cash from Operations has averaged -$29.9 million across 5 years, with a median of -$27.1 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations slumped 256.37% in 2023, then surged 63.19% in 2025.
• Over 5 years, Cash from Operations stood at -$19.1 million in 2022, then tumbled by 45.33% to -$27.7 million in 2023, then dropped by 18.91% to -$33.0 million in 2024, then jumped by 52.97% to -$15.5 million in 2025, then plunged by 34.04% to -$20.8 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$20.8 million, -$19.6 million, and -$15.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.